Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial

作者：Escudier B^*; Michaelson M D; Motzer R J; Hutson T E; Clark J I; Lim H Y; Porfiri E; Zalewski P; Kannourakis G; Staehler M; Tarazi J; Ro**rook B; Cisar L; Hariharan S; Kim S; Rini B I

来源：British Journal of Cancer, 2014, 110(12): 2821-2828.

DOI：10.1038/bjc.2014.244

Background: In the AXIS trial, axitinib prolonged progression-free survival (PFS) vs sorafenib in patients with advanced renal cell carcinoma (RCC) previously treated with sunitinib or cytokines. %26lt;br%26gt;Methods: In post hoc analyses, patients were grouped by objective response to prior therapy (yes vs no), prior therapy duration (%26lt; vs %26gt;= median), and tumour burden (baseline sum of the longest diameter %26lt; vs %26gt;= median). PFS and overall survival (OS), and safety by type and duration of prior therapy were evaluated. %26lt;br%26gt;Results: Response to prior therapy did not influence outcome with second-line axitinib or sorafenib. PFS was significantly longer in axitinib-treated patients who received longer prior cytokine treatment and sorafenib-treated patients with smaller tumour burden following sunitinib. Overall survival with the second-line therapy was longer in patients who received longer duration of prior therapy, although not significant in the sunitinib-to-axitinib sequence subgroup; OS was also longer in patients with smaller tumour burden, but not significant in the cytokine-to-axitinib sequence subgroup. Safety profiles differed modestly by type and duration of prior therapy. %26lt;br%26gt;Conclusions: AXIS data suggest that longer duration of the first-line therapy generally yields better outcome with the second-line therapy and that lack of response to first-line therapy does not preclude positive clinical outcomes with a second-line vascular endothelial growth factor-targeted agent in patients with advanced RCC.

• 出版日期2014-6-10